person · Reporting owner

Hilado Maria Teresa

Disclosed activity across 5 companies

Tapewire entity: 33120
SEC CIK: 0001587868

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allergan plcAGN · Entity 149298	Executive Vice President	April 03, 2018	April 05, 2018
CAMPBELL'S CoCPB · Entity 3700	Director	September 25, 2026	September 28, 2026
FULLER H B COFUL · Entity 4255	Director	July 01, 2021	July 02, 2021
ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278	Director	September 30, 2026	October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allergan plc

Report date April 03, 2018 · Filed April 05, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	25,911	Reported balance After 2018-04-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-04-03 · Tax withholding · Disposed 619 · Balance 25,911 F1: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

Filing footnotes · ownership attribution and instrument terms

F1: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

CAMPBELL'S Co

Report date September 25, 2026 · Filed September 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	45,050.93	Reported balance After 2026-09-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-25 · Grant · Acquired 2,332.86 · Balance 45,050.93 F1: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2: Phantom shares are fully vested. F3: The value of Phantom Stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4: Includes 731.99 shares acquired through dividend reinvestment since the reporting person's last report.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock.

F2: Phantom shares are fully vested.

F3: The value of Phantom Stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination.

F4: Includes 731.99 shares acquired through dividend reinvestment since the reporting person's last report.

FULLER H B CO

Report date July 01, 2021 · Filed July 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	30,167.16	Reported balance After 2021-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-01 · Grant · Acquired 2,090.43 · Balance 30,167.16 F1: These units convert into shares of common stock on a 1-for-1 basis. F2: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors Deferred Compensation Plan.
Common StockSEC Table I · non-derivative	Direct	1,345.5	Reported balance Holding disclosure · report date 2021-07-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,345.5

Filing footnotes · ownership attribution and instrument terms

F1: These units convert into shares of common stock on a 1-for-1 basis.

F2: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law.

F3: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors Deferred Compensation Plan.

ZIMMER BIOMET HOLDINGS, INC.

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85	Direct	13,392.107	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 375.626 · Balance 13,392.107 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4: Includes 32.614 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F4: Includes 32.614 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-12-08 transaction · row 1 1 source row Row 1 · 2021-12-08 · Disposition to issuer · Disposed 39,363 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted.

F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2018 Filed Mar 1, 2018 21:19 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	491.17	$50.39 Strike: $0.00	$24,750.06	Disclosure SEC source: 0001225208-18-004908 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,115.16 Underlying: Common Stock · 491.17 shares Expires not disclosed F1 · derivative.exercise_price: These units convert into shares of common stock on a 1-for-1 basis. F2 · derivative.exercise_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F2 · derivative.expiration_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · balance_after: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors Deferred Compensation Plan. Read SEC document
December 29, 2017 Filed Jan 2, 2018 16:40 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	1,175	$163.58	$192,206.50	Disclosure SEC source: 0001179110-18-000115 · edgar.xml · nonDerivative · entry 1 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,635 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
November 30, 2017 Filed Dec 4, 2017 18:13 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	437.51	$56.57 Strike: $0.00	$24,749.94	Disclosure SEC source: 0001225208-17-018036 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,623.99 Underlying: Common Stock · 437.51 shares Expires not disclosed F1 · derivative.exercise_price: These units convert into shares of common stock on a 1-for-1 basis. F2 · derivative.exercise_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F2 · derivative.expiration_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · balance_after: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors Deferred Compensation Plan. Read SEC document
October 26, 2017 Filed Oct 30, 2017 21:20 UTC	Allergan plc AGN · Entity 149298	Exercise / conversionPerformance Based Restricted Share Unit · Derivative	7,120	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-013550 · edgar.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. Read SEC document
October 26, 2017 Filed Oct 30, 2017 21:20 UTC	Allergan plc AGN · Entity 149298	Exercise / conversionOrdinary Shares, par value $0.0001	7,120	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-013550 · edgar.xml · nonDerivative · entry 1 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019. F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
August 31, 2017 Filed Sep 5, 2017 21:33 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	493.13	$50.19 Strike: $0.00	$24,750.19	Disclosure SEC source: 0001225208-17-014614 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145.94 Underlying: Common Stock · 493.13 shares Expires not disclosed F1 · derivative.exercise_price: These units convert into shares of common stock on a 1-for-1 basis. F2 · derivative.exercise_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F2 · derivative.expiration_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · balance_after: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors Deferred Compensation Plan. Read SEC document
July 13, 2017 Filed Jul 17, 2017 19:37 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	2,248.29	$51.15 Strike: $0.00	$115,000.03	Disclosure SEC source: 0001225208-17-012630 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,609.07 Underlying: Common Stock · 2,248.29 shares Expires not disclosed F1 · derivative.exercise_price: These units convert into shares of common stock on a 1-for-1 basis. F2 · derivative.exercise_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F2 · derivative.expiration_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · balance_after: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors 'Deferred Compensation Plan. Read SEC document
May 31, 2017 Filed Jun 1, 2017 18:50 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	487.68	$50.75 Strike: $0.00	$24,749.76	Disclosure SEC source: 0001225208-17-010697 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,327.3 Underlying: Common Stock · 487.68 shares Expires not disclosed F1 · derivative.exercise_price: These units convert into shares of common stock on a 1-for-1 basis. F2 · derivative.exercise_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F2 · derivative.expiration_date: These units will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · balance_after: This amount includes stock units acquired pursuant to a dividend equivalent feature of the Directors 'Deferred Compensation Plan. Read SEC document
April 03, 2017 Filed Apr 4, 2017 16:24 UTC	Allergan plc AGN · Entity 149298	GrantOrdinary Shares, par value $0.0001	6,311	$237.68	$1,499,998.48	Disclosure SEC source: 0001179110-17-005553 · edgar.xml · nonDerivative · entry 1 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,690 F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
February 28, 2017 Filed Mar 2, 2017 16:00 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	500.91	$49.41 Strike: $0.00	$24,749.96	Disclosure SEC source: 0001225208-17-005186 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,839.62 Underlying: Common Stock · 500.91 shares Expires not disclosed F2 · derivative.exercise_price: Deferred Compensation Plan: These units (acquired after 12-31-04) convert into shares of common stock on a 1-for-1 basis. F3 · derivative.exercise_date: Directors' Deferred Compensation Plan: These units (acquired after 12-31-04) will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · derivative.expiration_date: Directors' Deferred Compensation Plan: These units (acquired after 12-31-04) will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F4 · balance_after: Directors' Deferred Compensation Plan Dividend Reinvestment: This amount (acquired after 12-31-04) includes stock units acquired pursuant to a dividend equivalent feature of the Directors 'Deferred Compensation Plan. Read SEC document
November 30, 2016 Filed Dec 1, 2016 22:10 UTC	FULLER H B CO FUL · Entity 4255	GrantStock Units · Derivative	526.71	$46.99 Strike: $0.00	$24,750.10	Disclosure SEC source: 0001225208-16-042529 · doc4.xml · derivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,306.86 Underlying: Common Stock · 526.71 shares Expires not disclosed F2 · derivative.exercise_price: Deferred Compensation Plan: These units (acquired after 12-31-04) convert into shares of common stock on a 1-for-1 basis. F3 · derivative.exercise_date: Directors' Deferred Compensation Plan: These units (acquired after 12-31-04) will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F3 · derivative.expiration_date: Directors' Deferred Compensation Plan: These units (acquired after 12-31-04) will be converted into shares of common stock upon retirement, death, disability or certain specified events, all as defined in such plan, subject to holding periods required by law. F4 · balance_after: Directors' Deferred Compensation Plan Dividend Reinvestment: This amount (acquired after 12-31-04) includes stock units acquired pursuant to a dividend equivalent feature of the Directors 'Deferred Compensation Plan. Read SEC document
November 11, 2016 Filed Nov 15, 2016 17:18 UTC	Allergan plc AGN · Entity 149298	PurchaseOrdinary Shares, par value $0.0001	720	$208.05	$149,792.62	Disclosure SEC source: 0001179110-16-031625 · edgar.xml · nonDerivative · entry 2 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,379 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $208.00 to 208.06, inclusive. The reporting person undertakes to provide Allergan plc, any security holder of Allergan plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in footnote (1) of this Form 4. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
November 11, 2016 Filed Nov 15, 2016 17:18 UTC	Allergan plc AGN · Entity 149298	PurchaseOrdinary Shares, par value $0.0001	702	$213.31	$149,743.62	Disclosure SEC source: 0001179110-16-031625 · edgar.xml · nonDerivative · entry 1 Hilado Maria Teresa · CIK 0001587868 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,659 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.